



National Institute of  
Allergy and  
Infectious Diseases



Reading Hospital

TOWER HEALTH

Advancing Health. Transforming Lives.



Drexel  
UNIVERSITY

**CLINICAL TRIALS OFFICE**

[research@towerhealth.org](mailto:research@towerhealth.org)

**Full Title** A Prospective Cohort Study to Assess Longitudinal Immune Responses in Hospitalized Patients with COVID-19 DOB, Suite 355  
484-628-8585

Immunophenotyping Assessment in a CCOVID-19 COHORT  
(IMPACC)

**Principal Investigator** Debra Powell, MD

**Sub-Investigators** James Kim, MD

**Primary Study Objectives**

- Describe the relationship between specific immunologic assessments and the severity of illness in hospitalized patients with COVID-19
- Detail the relationship between burden of disease and severity of illness in hospitalized patients with COVID-19
- Describe risk factors associated with requirements for respiratory support measures in hospitalized patients with COVID-19
- Describe immunologic characteristics associated with disease-severity, as reflected by mortality and specific measures of critical illness in hospitalized patients with COVID-19

**Inclusion Criteria**

- Male or female participants > age 18 years at the time of hospitalization
- Admitted to a hospital with presumptive or documented COVID-19, with confirmation of SARS-CoV-2 infection by PCR.
- Participant and/or surrogate understands the data to be collected and the study procedures and is willing to participate in the surveillance cohort

**Exclusion Criteria**

- Medical problems or conditions such as pregnancy which might impact interpretation of the immunologic data obtained



National Institute of  
Allergy and  
Infectious Diseases



Reading Hospital

TOWER HEALTH

Advancing Health. Transforming Lives.



Drexel  
UNIVERSITY

**CLINICAL TRIALS OFFICE**

[research@towerhealth.org](mailto:research@towerhealth.org)

DOB, Suite 355

484-628-8585

(Exclusion criteria continued...)

- Underlying medical problems which, in the opinion of the investigator may be associated with mortality unrelated to COVID-19 within 48 hours of hospitalization, or a decision by the patient or surrogate prior to hospitalization to limit care to comfort measures

**Affiliations &  
Sponsors**

NIH-NIAD, Drexel

**Keywords**

COVID-19, SARS-CoV-2, coronavirus, immunophenotyping